Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.61 (
caspase-8
)
6,833
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pancreatic cancer remains a major unsolved health problem lacking a potent therapeutic option. Our previous studies showed that the
ribosomal protein L39
(
RPL39
) gene was up-regulated after long-term silencing of oncogenic KRAS in pancreatic cancer PANC-1 cells, which indicated that
RPL39
may be important for pancreatic cancer development and survival. In the current study, small interfering RNA (siRNA) targeting of the
RPL39
gene was performed to determine the effects of the
RPL39
gene on growth of pancreatic cancer PANC-1 and BxPC-3 cells in vitro and in vivo. Results from in vitro experiments showed that knockdown of
RPL39
expression with
RPL39
-siRNA suppressed cell proliferation and specifically enhanced cell apoptosis significantly in both PANC-1 and BxPC-3 cells. The increase of
caspase-8
activities and the loss of mitochondrial membrane potential after
RPL39
silencing indicated that the
RPL39
gene may be involved in
caspase-8
-related mitochondrial apoptosis. Further, treatment with the
RPL39
-siRNA inhibited the growth of a human pancreatic cancer xenograft in BALB/c nude mice, accompanied by a decreased expression of
RPL39
. In the xenograft tumors with injection of
RPL39
-siRNA, the expressions of Ki-67 and CD31 were significantly down-regulated, and apoptosis was markedly induced. Our findings suggested that siRNA against the
RPL39
gene may be of value for gene therapy of pancreatic cancer.
...
PMID:Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo. 2479 81
